Skip to main content

06-16-2018 | Devices and technology | Review | Article

Transplantation of Macroencapsulated Insulin-Producing Cells

Current Diabetes Reports

Authors: Albert J. Hwa, Gordon C. Weir

Publisher: Springer US


Purpose of Review

There is considerable interest in using macroencapsulation devices as a delivery strategy for transplanting insulin-producing cells. This review aims to summarize recent advances, to highlight remaining challenges, and to provide recommendations for the field.

Recent Findings

A variety of new device designs have been reported to improve biocompatibility and to provide protection for islet/beta cells from immune destruction while allowing continuous secretion of insulin. Some of these new approaches are in clinical trials, but more research is needed to determine how sufficient beta-cell mass can be transplanted in a clinically applicable device size, and that insulin is secreted with kinetics that will safely provide adequate controls of glucose levels.


Macroencapsulation is a potential solution to transplant beta cells without immunosuppression in diabetes patients, but new strategies must be developed to show that this approach is feasible.

Please log in to get access to this content

Related topics

CME-accredited GLP-1RAs webcast

Learn more about GLP-1RAs with John Wilding, Julie Lovshin and Kamlesh Khunti

CME-accredited GLP-1RAs webcast on real-world data

Led by Melanie Davies, Stewart Harris & Takashi Kadowaki, this on-demand webcast focuses on treatment with GLP-1RAs, based on real-world data, and the emerging landscape of GLP-1RAs in the context of approved guidelines.

Image Credits